# ZUMA-5 (NCT03105336)

> A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03105336
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Kite, A Gilead Company
- Conditions: Follicular Lymphoma; Marginal Zone Lymphoma; Indolent Non-Hodgkin Lymphoma
- Interventions: Axicabtagene ciloleucel; Cyclophosphamide; Fludarabine
- Enrollment: 159
- Primary outcome: Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment

## Commentary we found

- YouTube: 46
- Podcasts: 42
- X threads: 14

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zuma-5-nct03105336

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03105336", "email": "<work email>"}; the inbox owner confirms by the emailed link.